3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
28
Lymphoma
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Breast Neoplasms
22
Multiple Myeloma
21
Lymphoma, Large B-Cell, Diffuse
21
Carcinoma, Non-Small-Cell Lung
21
Lymphoma, Non-Hodgkin
19
Lymphoma, Mantle-Cell
17
Lymphoma, Follicular
16
Hodgkin Disease
15
Lymphoma, T-Cell, Cutaneous
13
Glioblastoma
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Brain Neoplasms
12
Recurrence
11
Myelodysplastic Syndromes
11
Mycosis Fungoides
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia
11
Burkitt Lymphoma
11
Neuroblastoma
10
Neoplasms
10
Sezary Syndrome
9
Congenital Abnormalities
9
Prostatic Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
8
Squamous Cell Carcinoma of Head and Neck
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms, Plasma Cell
7
Interventions
eltrombopag
14
romiplostim
7
avatrombopag
6
Cytarabine
6
Platelet Transfusion
5
Filgrastim
4
Etoposide
4
Carboplatin
4
oprelvekin
3
Tranexamic Acid
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Daunorubicin
3
Cyclophosphamide
3
Busulfan
3
hetrombopag
2
fludarabine phosphate
2
Tretinoin
2
Thrombopoietin
2
Lenalidomide
2
Interleukin-11
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Doxorubicin
2
Cyclosporine
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
sodium thiosulfate
1
siltuximab
1
sargramostim
1
raltitrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thrombocytopenia
×
Vorinostat
×
Clear all
NCT01500538
2016-02-15
VEIL
Peter MacCallum Cancer Centre, Australia
Phase 2
Terminated
1 enrolled